Latest News

Date Title Topic
28 Mar 2017 EMA Adopts a New Indication for Pembrolizumab Haematologic malignancies - Cancer Immunology and Immunotherapy
26 Mar 2017 EMA Adopts a New Indication for Nivolumab Head and neck cancers - Cancer Immunology and Immunotherapy
24 Mar 2017 FDA Grants Accelerated Approval to Avelumab Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
16 Mar 2017 FDA Grants Accelerated Approval to Pembrolizumab for the Treatment of Classical Hodgkin Lymphoma Cancer Immunology and Immunotherapy
Breast Cancer
15 Mar 2017 FDA Approves Ribociclib as Initial Treatment for Postmenopausal Women with HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
14 Mar 2017 EMA Reviewing Cancer Medicine Docetaxel Anticancer agents & Biologic therapy
13 Mar 2017 EMA’s PRAC Concludes Assessment of Gadolinium Agents and Recommends Regulatory Actions, Including Suspension of Some Marketing Authorisations Diagnosis, Imaging and Staging
10 Mar 2017 Use of imatinib in CML has pointed oncology in a new direction Haematologic malignancies - Anticancer agents & Biologic therapy
08 Mar 2017 Clarification of Hepatitis B Virus Status Needed Before Starting Treatment with Pomalidomide Anticancer agents & Biologic therapy
07 Mar 2017 FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhoea Endocrine and neuroendocrine tumours
07 Mar 2017 Press Release: Targeted Anticancer Therapies (TAT) Congress Becomes an Annual ESMO Event